Skip to main content
SpringerLink
Log in

A critical update on prognostic and predictive biomarkers in malignant pleural mesothelioma

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Abstract

Malignant pleural mesothelioma (MPM) is a devastating and treatment-resistant disease. Currently, well-established prognostic and predictive biomarkers are rare in clinical practice, whereas there is a whole body of various MPM biomarker studies published in medical literature in the past decades. Besides well-established pathological parameters, including histological subtype, disease stage, or level of lymph node involvement, blood parameters and circulating proteins related to a proinflammatory phenotype are emerging as prognostic biomarkers. Here we provide an overview about the current status of prognostic and predictive biomarkers in MPM, with a strong emphasis on their applicability in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol. 2009;27(12):2081–90.

    Article  CAS  PubMed  Google Scholar 

  2. van Zandwijk N, Clarke C, Henderson D, Musk AW, Fong K, Nowak A, et al. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis. 2013;5(6):E254–307.

    PubMed Central  PubMed  Google Scholar 

  3. Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 2014;83(2):240–5.

    Article  PubMed  Google Scholar 

  4. de Perrot M, Feld R, Cho BC, Bezjak A, Anraku M, Burkes R, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27(9):1413–8.

    Article  PubMed  Google Scholar 

  5. Van Schil PE, Baas P, Gaafar R, Maat AP, Van de Pol M, Hasan B, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J. 2010;36(6):1362–9.

    Article  CAS  PubMed  Google Scholar 

  6. Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12(8):763–72.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Ghanim B, Hoda MA, Klikovits T, Winter MP, Alimohammadi A, Grusch M, et al. Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma. Br J Cancer. 2014;110(4):984–90.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Baas P. Predictive and prognostic factors in malignant pleural mesothelioma. Curr Opin Oncol. 2003;15(2):127–30.

    Article  PubMed  Google Scholar 

  9. Pantazopoulos I, Boura P, Xanthos T, Syrigos K. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma. Eur Respir J. 2013;41(3):706–15.

    Article  CAS  PubMed  Google Scholar 

  10. Linton A, van Zandwijk N, Reid G, Clarke S, Cao C, Kao S. Inflammation in malignant mesothelioma—friend or foe? Ann Cardiothorac Surg. 2012;1(4):516–22.

    PubMed Central  PubMed  Google Scholar 

  11. Ghanim B, Hoda MA, Winter MP, Klikovits T, Alimohammadi A, Hegedus B, et al. Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis. Ann Surg. 2012;256(2):357–62.

    Article  PubMed  Google Scholar 

  12. Pinato DJ, Mauri FA, Ramakrishnan R, Wahab L, Lloyd T, Sharma R. Inflammation-based prognostic indices in malignant pleural mesothelioma. J Thorac Oncol. 2012;7(3):587–94.

    Article  CAS  PubMed  Google Scholar 

  13. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16(1):145–52.

    CAS  PubMed  Google Scholar 

  14. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998;113(3):723–31.

    Article  CAS  PubMed  Google Scholar 

  15. Baldi A, Santini D, Vasaturo F, Santini M, Vicidomini G, Di Marino MP, et al. Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma. Thorax. 2004;59(5):428–33.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Bitanihirwe BK, Meerang M, Friess M, Soltermann A, Frischknecht L, Thies S, et al. PI3K/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy. J Thorac Oncol. 2014;9(2):239–47.

    Article  CAS  PubMed  Google Scholar 

  17. Zimling ZG, Sorensen JB, Gerds TA, Bech C, Andersen CB, Santoni-Rugiu E. Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival. J Thorac Oncol. 2012;7(1):249–56.

    Article  CAS  PubMed  Google Scholar 

  18. Righi L, Papotti MG, Ceppi P, Bille A, Bacillo E, Molinaro L, et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol. 2010;28(9):1534–9.

    Article  CAS  PubMed  Google Scholar 

  19. Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010;35(3):479–95.

    Article  CAS  PubMed  Google Scholar 

  20. Stahel RA, Weder W, Lievens Y, Felip E. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl. 5):v126–8.

  21. Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O’Byrne KJ. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax. 2000;55(9):731–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Kao SC, Klebe S, Henderson DW, Reid G, Chatfield M, Armstrong NJ, et al. Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. J Thorac Oncol. 2011;6(11):1923–9.

    Article  PubMed  Google Scholar 

  23. Meniawy TM, Creaney J, Lake RA, Nowak AK. Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma. Br J Cancer. 2013;109(7):1813–20.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Tanrikulu AC, Abakay A, Kaplan MA, Kucukoner M, Palanci Y, Evliyaoglu O, et al. A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma. Respiration. 2010;80(6):480–7.

    Article  PubMed  Google Scholar 

  25. Baud M, Strano S, Dechartres A, Jouni R, Triponez F, Chouaid C, et al. Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis. J Thorac Cardiovasc Surg. 2013;145(5):1305–11.

    Article  PubMed  Google Scholar 

  26. Nojiri S, Gemba K, Aoe K, Kato K, Yamaguchi T, Sato T, et al. Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan. Jpn J Clin Oncol. 2011;41(1):32–9.

    Article  PubMed  Google Scholar 

  27. Aigner C, Hoda MA, Lang G, Taghavi S, Marta G, Klepetko W. Outcome after extrapleural pneumonectomy for malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2008;34(1):204–7.

    Article  PubMed  Google Scholar 

  28. Kao SC, Vardy J, Chatfield M, Corte P, Pavlakis N, Clarke C, et al. Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board. Clin Lung Cancer. 2013;14(1):70–7.

    Article  PubMed  Google Scholar 

  29. Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med. 2012;367(15):1417–27.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This review was, in part, supported by grants from the Oesterreichische Nationalbank (#13424 to Walter Klepetko and #14574 to Mir Alireza Hoda), from the Burgermeister Fond of Vienna (#9014 to Mir Alireza Hoda), from the National Development Agency, Hungary (KTIA AIK 12-1-2013-0041 to Balazs Dome), and from the Vienna Fund for Innovative Interdisciplinary Cancer Research (to Balazs Dome and Mir Alireza Hoda).

Conflict of interest

The authors declare that there are no actual or potential conflicts of interest in relation to this article.

Author information

Authors and Affiliations

  1. Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna, Währinger Gürtel 18–20, 1090, Vienna, Austria

    Bahil Ghanim MD, Mir Alireza Hoda MD, Thomas Klikovits MD, Balazs Dome MD, PhD, Walter Klepetko MD & Balazs Hegedus PhD

  2. Institute of Cancer Research, Department of Internal Medicine I, Medical University of Vienna, Borschkegasse 8a, 1090, Vienna, Austria

    Bahil Ghanim MD, Mir Alireza Hoda MD, Michael Grusch PhD, Martin Filipits PhD, Walter Berger PhD & Balazs Hegedus PhD

Authors
  1. Bahil Ghanim MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mir Alireza Hoda MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas Klikovits MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Balazs Dome MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael Grusch PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Martin Filipits PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Walter Klepetko MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Walter Berger PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Balazs Hegedus PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Balazs Hegedus PhD.

Additional information

Part of this manuscript has been presented by Bahil Ghanim at the 11th “PneumoUpdate” (12th to 14th June 2014, Igls, Tyrol, Austria).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ghanim, B., Hoda, M., Klikovits, T. et al. A critical update on prognostic and predictive biomarkers in malignant pleural mesothelioma. memo 8, 52–56 (2015). https://doi.org/10.1007/s12254-014-0166-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-014-0166-4

Keywords

Search

Navigation